ASCO2021-话题@MedSci

#ASCO2021#

16篇内容 | 767人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=971438, encodeId=bf439e143882, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 16 |ctDNA在预测结直肠癌复发及全程管理中的潜在作用, objectType=article, longId=212111, objectId=4d9a21211161, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/102373157-95011716.1910x1000.jpg, objectUrl=/article/show_article.do?id=4d9a21211161, replyNumber=0, likeNumber=95, createdTime=2021-06-07, rootId=0, userName=ms6000000398323201, userId=d3c45510476, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d9a21211161, moduleTitle=ASCO 2021: 摘要概览与展望 16 |ctDNA在预测结直肠癌复发及全程管理中的潜在作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d9a21211161)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=971439, encodeId=e2289e14396b, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021：摘要概览与展望15 |乳腺癌最新研究概览（ER阳性乳腺癌专栏）, objectType=article, longId=212109, objectId=017e212109d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=017e212109d1, replyNumber=0, likeNumber=84, createdTime=2021-06-07, rootId=0, userName=ms6000000398323201, userId=d3c45510476, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017e212109d1, moduleTitle=ASCO 2021：摘要概览与展望15 |乳腺癌最新研究概览（ER阳性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=017e212109d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=971442, encodeId=0f829e1442bd, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021：皮肤癌免疫疗法新进展（持续更新）, objectType=article, longId=212405, objectId=c84d21240500, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202166/1622995177648_5296193.jpg, objectUrl=/article/show_article.do?id=c84d21240500, replyNumber=0, likeNumber=100, createdTime=2021-06-07, rootId=0, userName=ms6000000398323201, userId=d3c45510476, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84d21240500, moduleTitle=ASCO 2021：皮肤癌免疫疗法新进展（持续更新）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84d21240500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=971278, encodeId=2c8b9e12789d, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021开幕，大流行背景下癌症治疗公平性受关注, objectType=article, longId=212350, objectId=6e3f21235068, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/1994f57847dc4b449b50cfa270ce289c.jpg, objectUrl=/article/show_article.do?id=6e3f21235068, replyNumber=0, likeNumber=90, createdTime=2021-06-06, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e3f21235068, moduleTitle=ASCO 2021开幕，大流行背景下癌症治疗公平性受关注, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e3f21235068)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968976, encodeId=51ed9689e686, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021：摘要概览与展望11 |乳腺癌最新研究概览（浸润性乳腺癌专栏）, objectType=article, longId=211922, objectId=6faa2119225a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=6faa2119225a, replyNumber=0, likeNumber=65, createdTime=2021-05-27, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6faa2119225a, moduleTitle=ASCO 2021：摘要概览与展望11 |乳腺癌最新研究概览（浸润性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6faa2119225a)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！, objectType=article, longId=211864, objectId=907c211864e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/147963-medical-pills-capsules.jpg, objectUrl=/article/show_article.do?id=907c211864e9, replyNumber=0, likeNumber=90, createdTime=2021-05-26, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=907c211864e9, moduleTitle=ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=907c211864e9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968722, encodeId=1b9d968e22ad, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, objectType=article, longId=211898, objectId=a7cd21189859, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021526/1622019338270_2239729.png, objectUrl=/article/show_article.do?id=a7cd21189859, replyNumber=0, likeNumber=77, createdTime=2021-05-26, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7cd21189859, moduleTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7cd21189859)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968699, encodeId=fbe996869900, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 6 | 肝细胞癌重磅研究一览, objectType=article, longId=211894, objectId=b2b42118942f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=b2b42118942f, replyNumber=0, likeNumber=79, createdTime=2021-05-26, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2b42118942f, moduleTitle=ASCO 2021: 摘要概览与展望 6 | 肝细胞癌重磅研究一览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2b42118942f)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968698, encodeId=9a75968698f7, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021 :摘要概览与展望8 | 乳腺癌最新研究概览（男性乳腺癌专栏）, objectType=article, longId=211897, objectId=c66a21189e21, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=c66a21189e21, replyNumber=0, likeNumber=59, createdTime=2021-05-26, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66a21189e21, moduleTitle=ASCO 2021 :摘要概览与展望8 | 乳腺癌最新研究概览（男性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66a21189e21)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968526, encodeId=b4f396852673, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注, objectType=article, longId=211839, objectId=d07121183975, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/d9b7b84f774c4db19bb13ae0578df873.jpg, objectUrl=/article/show_article.do?id=d07121183975, replyNumber=0, likeNumber=66, createdTime=2021-05-26, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d07121183975, moduleTitle=ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d07121183975)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=968397, encodeId=839b96839eae, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 4｜小细胞肺癌领域研究速递, objectType=article, longId=211823, objectId=63f3211823c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=63f3211823c9, replyNumber=0, likeNumber=80, createdTime=2021-05-25, rootId=0, userName=可盐可甜, userId=cf665497903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63f3211823c9, moduleTitle=ASCO 2021: 摘要概览与展望 4｜小细胞肺癌领域研究速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63f3211823c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=968163, encodeId=653096816329, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 3 | 罗氏阿特珠单抗有望成为第一个被批准用于围手术期治疗非小细胞肺癌的免疫疗法, objectType=article, longId=211750, objectId=3490211e50fa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/723baf38b20245fba2ee703c7255e9c3.jpg, objectUrl=/article/show_article.do?id=3490211e50fa, replyNumber=0, likeNumber=0, createdTime=2021-05-24, rootId=0, userName=许愿精灵, userId=c10f5505974, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3490211e50fa, moduleTitle=ASCO 2021: 摘要概览与展望 3 | 罗氏阿特珠单抗有望成为第一个被批准用于围手术期治疗非小细胞肺癌的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3490211e50fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=967987, encodeId=743d96e987c2, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=晚期癌症呼吸困难的治疗：ASCO指南, objectType=guider, longId=13284, objectId=695771c00206a541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=695771c00206a541, replyNumber=0, likeNumber=55, createdTime=2021-05-23, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=695771c00206a541, moduleTitle=晚期癌症呼吸困难的治疗：ASCO指南, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=695771c00206a541)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=967986, encodeId=df5796e98673, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021: 摘要概览与展望 2, objectType=article, longId=211710, objectId=08e5211e109c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/45993c6b66954e9bab90f0270820f0dc.jpg, objectUrl=/article/show_article.do?id=08e5211e109c, replyNumber=0, likeNumber=105, createdTime=2021-05-23, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08e5211e109c, moduleTitle=ASCO 2021: 摘要概览与展望 2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e5211e109c)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=967985, encodeId=d1e796e98500, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, objectTitle=ASCO 2021：摘要概览与展望 1, objectType=article, longId=211709, objectId=59a1211e095b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210516/48b101b674b44586b11f638997a1955d.jpg, objectUrl=/article/show_article.do?id=59a1211e095b, replyNumber=0, likeNumber=73, createdTime=2021-05-23, rootId=0, userName=MedSciZeng, userId=078e1614372, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a1211e095b, moduleTitle=ASCO 2021：摘要概览与展望 1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a1211e095b)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] MedSciZeng

ASCO2021

2021-05-23

ms6000000398323201 (审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 16 |ctDNA在预测结直肠癌复发及全程管理中的潜在作用

2021-06-07

ms6000000398323201 (审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021：摘要概览与展望15 |乳腺癌最新研究概览（ER阳性乳腺癌专栏）

2021-06-07

ms6000000398323201 (审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021：皮肤癌免疫疗法新进展（持续更新）

2021-06-07

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021开幕，大流行背景下癌症治疗公平性受关注

2021-06-06

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021：摘要概览与展望11 |乳腺癌最新研究概览（浸润性乳腺癌专栏）

2021-05-27

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展！

2021-05-26

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案

2021-05-26

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 6 | 肝细胞癌重磅研究一览

2021-05-26

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021 :摘要概览与展望8 | 乳腺癌最新研究概览（男性乳腺癌专栏）

2021-05-26

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注

2021-05-26

可盐可甜 (审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 4｜小细胞肺癌领域研究速递

2021-05-25

许愿精灵 (审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 3 | 罗氏阿特珠单抗有望成为第一个被批准用于围手术期治疗非小细胞肺癌的免疫疗法

2021-05-24

(审核中...)

前往app查看评论内容

#ASCO2021#

晚期癌症呼吸困难的治疗：ASCO指南

2021-05-23

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021: 摘要概览与展望 2

2021-05-23

(审核中...)

前往app查看评论内容

#ASCO2021#

ASCO 2021：摘要概览与展望 1

2021-05-23

科室
- - 订阅+
  - 更多科室
工具
服务